Pilot Evaluation of the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Women with Hair Loss

Main Article Content

Spencer Hawkins
Chesahna Kindred
Michelle Peters
Adam Leavitt
Matt Leavitt

Keywords

Female pattern hair loss, Nutraceuticals, Non-scarring alopecia, Hair density, Phototrichogram, Canfield HairMetrix, Scarring alopecia, Gummy supplement

Abstract

Background: Hair loss in women is a prevalent condition with significant psychosocial impact, yet therapeutic options remain limited. Nutraceutical supplements are widely used as adjunctive therapy; however, few formulations—particularly gummy-based delivery formats designed to improve adherence—have been evaluated using objective imaging endpoints.


Methods: This prospective, single-center, single-arm pilot study evaluated the safety and efficacy of Xtressé™, a dermatologist-developed gummy nutraceutical, in 24 women with self-perceived hair thinning. Participants consumed two gummies daily for four months. Seventeen participants (11 non-scarring alopecia, 6 scarring alopecia) completed the study. Primary outcomes included change in hair density by Canfield HairMetrix® phototrichogram analysis and change in global alopecia severity by SOCAi Vision™.


Results: Among participants with non-scarring alopecia, 81.8% met responder criteria by Canfield HairMetrix® phototrichogram analysis, with mean increases in total hair density (+7.35%, 11.4 hairs/cm²) and terminal hair density (+6.81%, 10.2 hairs/cm²); 63.6% also demonstrated improvement in global scalp coverage by SOCAi Vision™. Among participants with scarring alopecia, localized phototrichogram parameters within scarred regions of interest declined (16.7% responder rate by Canfield), consistent with irreversible follicular loss, whereas global imaging detected improvement in surrounding non-scarred scalp in 66.7% by SOCAi Vision™. Mean relative improvement in global coverage exceeded 20% among SOCAi responders in both subgroups. No adverse events were reported.


Conclusion: Xtressé™ was safe, well tolerated, and associated with measurable improvements in hair parameters among women with non-scarring alopecia. These findings support the potential role of multi-ingredient nutraceutical therapy as adjunctive treatment for hair loss. Larger, controlled trials are warranted.

References

1. Messenger AG, Sinclair RD. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol. 2006;155(5):926-930.

2. Dlova NC, Fabbrocini G, Lauro C, Spano M, Tosti A, Hift RJ. Quality of life in South African Black women with alopecia: a pilot study. Int J Dermatol. 2016;55(8):875-881.

3. Trüeb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009;1(1):6-14.

4. Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Barbieri JS. Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol. 2023;159(1):79-86.

5. Ablon G. A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. Dermatol Res Pract. 2015;2015:841570.

6. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.

7. Gudobba C, Ezaldein HH, Scott JF, Bordone LA. Automating hair loss labels for universally scoring alopecia from images: rethinking alopecia scores. JAMA Dermatol. 2023;159(2):143-150.

8. Sacha JP, Schaefer R, Batchelor D, Gale F, Sherwood O, Sherrill J. Machine learning algorithm for automated hair counting and analysis. Int J Cosmet Sci. 2021;43(S1):S34-S41.

Most read articles by the same author(s)